SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 23, 2021
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
| Nevada | 001-38543 | 26-1265381 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 400 Water Street, Suite 200, Rochester, MI | 48307 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 248.651.6568
|
___________________________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||
| Common Stock | OPRX | Nasdaq Capital Market |
SECTION 8 – Other Events
| Item 8.01 | Other Events |
On February 23, 2021, we issued a press release announcing that our senior vice president and principal of agency channels, Angelo Campano, has been named to MM+M’s 2021 ‘40 Under 40’ list for his accomplishments and contributions to the healthcare marketing industry. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits |
| 99.1 | Press release, dated February 23, 2021 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OptimizeRx Corporation
| /s/ Douglas Baker | ||
| Douglas Baker | ||
| Chief Financial Officer | ||
| Date: February 23, 2021 |
2
Exhibit 99.1
OptimizeRx’s Angelo Campano Named to MM+M 40 Under 40 List
List Celebrates Accomplished Young Talent in Medical Marketing
ROCHESTER, Mich. – February 23, 2021 – OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced its senior vice president and principal of agency channels, Angelo Campano, has been named to MM+M’s 2021 ‘40 Under 40’ list for his accomplishments and contributions to the healthcare marketing industry.
The 40 Under 40 list shines a light on the young marketers whose leadership, thinking and digital know-how have contributed to the industry’s continued growth under challenging market conditions. The list includes individuals ranging from pharma and biotech companies, medical marketing agencies, device manufacturers, analytics firms and health media.
The award is sponsored by MM+M, the media-of-record for pharmaceutical marketing and commercialization delivering the most balanced and relevant coverage of its subject matter.
Campano has more than 18 years
of experience leading digital channel partnerships and innovation.
He has been an innovator and leader in electronic health record (EHR) workflow and hub services. Over the course of his career,
he has established partnerships with more than 245 EHR platforms, 100 specialty pharma partners and five communications partners
to bring life sciences resources to more places at the point-of-care. Campano received PM360’s ELITE Innovator Award in
2017 and was inducted into the Medical Advertising Hall of Fame in 2014.
“As an industry trailblazer, Angelo has dedicated his career to bringing innovation to the point-of-care,” said OptimizeRx chief commercial officer, Steve Silvestro. “This award reflects the tremendous positive impact he has had on our industry and the companies he has served. We’re fortunate to have an industry leader of Angelo’s caliber on our team.”
MM+M’s GM and editor-in-chief, Steve Madden, commented: “When we started the 40 Under 40 program last year, we were blown away by the volume of smart young people doing high-caliber work. As they assume greater leadership roles, the industry should feel very secure about its fortunes in the years ahead.”
See the full list of honorees at www.mmm40under40.com/home.
MM+M will celebrate the 2021 honorees during a virtual event scheduled for March 25, 2021.
About MM+M
First published in 1966 as Medical Marketing & Media, MM+M is the media brand of record for pharmaceutical marketing and commercialization, delivering the most balanced and relevant coverage of the growing industry. The title produces an essential mix of online breaking news and analysis combined with monthly print features — timely, objective, original editorial content for an executive audience of leaders and thinkers who work in pharma, medical device, diagnostics and greater healthcare marketing. MM+M also develops conferences and live and virtual events, and engineers the industry’s premier awards program, the MM+M Awards.
About OptimizeRx
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding
Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be
used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or
revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual
results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks
and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation,
competition and other material risks.
OptimizeRx Contact
Doug Baker, CFO
Tel (248) 651-6568 (x807)
dbaker@optimizerx.com
Media Relations Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact
Ron Both, CMA
Tel (949) 432-7557
Email Contact